

553,915

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/098600 A1(51) International Patent Classification⁷: **A61K 31/47**,
31/4709, A61P 25/18, 25/26, 25/28(21) International Application Number:
PCT/GB2004/001934

(22) International Filing Date: 4 May 2004 (04.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0301320-8 6 May 2003 (06.05.2003) SE(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BECKER, Christopher** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **COMSTOCK, Jeanne** [US/US]; Biomeasure, Inc, 30 Mary Drive, West Boylston, Massachusetts 01583 (US). **MICHNE, William, F** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **MURPHY, Megan** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **PHILLIPS, Eifion** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **ROSAMOND,****James, D** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **SIMPSON, Thomas, R** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850 (US).(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POSITIVE MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS



(I)



(II)

(57) Abstract: Compounds of Formula (I) or Formula (II) wherein R₁, X and Ar are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

WO 2004/098600 A1